^
Association details:
| Biomarker: | HLA-A*30 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
184P - Patient-specific HLA-I genotypes predict response to immune checkpoint blockade
Published date:
10/16/2023
Excerpt:
In the NSCLC subgroup, patients with HLA-A01 subtypes were significantly associated with better OS (hazard ratio (HR): 0.42, 95%CI: 0.22-0.81, p= 0.010); meanwhile, HLA-A02 was associated with worse OS (HR: 1.95, 95%CI: 1.09-3.49, p= 0.024)...HLA-A status predicted clinical outcomes of patients receiving ICB.
